Skip to content

Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients

Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07236723
Enrollment
57
Registered
2025-11-19
Start date
2025-12-31
Completion date
2026-12-31
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathy

Keywords

vitamin d, nerve growth factor and diabetic neuropathy

Brief summary

study the relationship of vitamin d with nerve growth factor level and nerve conduction studies in adult male type 2 diabetic neuropathy patients

Detailed description

Diabetic peripheral neuropathy (DPN) is one of the most frequent microvascular complications of both type1 (T1DM) and type2 diabetes mellitus (T2DM) . It involves damage to the peripheral nerves, leading to symptoms such as numbness, tingling, pain, and loss of sensation in the extremities, especially the feet and hands . It is the primary risk factor for lower limb ulcers, amputations and consequent disabling, that can significantly affect a person's quality of life. Unfortunately, the exact pathogenesis of diabetic neuropathy is complex and multifactorial. However, several studies have shown that increased levels of blood glucose leads to several neuronal changes as accumulation of advanced glycation end products, mitochondrial impairment and DNA damage. Furthermore, Vitamin D deficiency is more common in people with T2DM, contributing its pathogenesis in many ways, including impairment of insulin secretion and increasing insulin resistance. Moreover, previous studies reported that low level of vitamin D is correlated with the presence and severity of sensory neuropathy . However, its pathogenesis has not yet been established. Nerve growth factor (NGF) is a neurotrophic factor playing a major role in adult peripheral nerve system. It works by increasing nerve cell regeneration and decreasing degeneration, so NGF decreased levels induce peripheral nerve lesion in diabetic patients. Several studies indicate that vitamin D may play a role in nutrition and protection of peripheral nerves as nerve cells and glial cells rich in vitamin D receptors, So vitamin D may have a potential effect in DPN by neuro-protection as it protect against apoptosis and degeneration, as well as it can trigger production of NGF helping preservation of neurons. Thus, we hypothesize that vitamin D, by regulating NGF expression, could help nerve regeneration and improve outcomes in patients with DPN.

Interventions

Assessment of neuropathy by nerve conduction studies of sural and tibial nerves in both lower extremities.

nerve growth factor level using its corresponding ELISA kit

25(OH) vitamin D serum level using its corresponding ELISA kit

Sponsors

Aswan University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult male patients 40 -65 years' old who have type 2 diabetes mellitus on oral hypoglycemic , non-diabetic healthy subjects of matched age and type 2male diabetic neuropathy patients of matched age .

Exclusion criteria

* Cardiac patients. * Patients who have transient ischemic attack or stroke. * Patients with inflammatory rheumatic diseases. * Patients with malignant diseases. * Hyperparathyroidism. * Hypothyroidism. * Renal impairment with renal replacement therapy. * Liver diseases. * Patients on vitamin D supplementation. * Patients on vitamin B12 supplementation.

Design outcomes

Primary

MeasureTime frameDescription
study the relation of vitamin d and nerve growth factor with nerve conduction studies in type 2 diabetic neuropathy male patientsone year1. Difference in vitamin D level between diabetic neuropathy patients, diabetic patients without neuropathy and healthy subjects. 2. Difference in serum nerve growth factor level between diabetic neuropathy patients, diabetic patients without neuropathy and healthy subjects.

Countries

Egypt

Contacts

Primary ContactMarwa Nasry Elbadry, physiology demonstrator
marwanasry666@gmail.com02+01126060796

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026